Baseline HIV-1 RNA level and CD4 cell count predict time to loss of virologic response to nelfinavir, but not lopinavir/ritonavir, in antiretroviral therapy-naive patients

Journal of Infectious Diseases

Volumn 190, Issue 2, 2004, Pages 280-284

  King, Martin S ^a,g   Bernstein, Barry M ^a   Walmsley, Sharon L ^d   Sherer, Renslow ^b   Feinberg, Judith ^c   Sanne, Ian ^f   Cernohous, Paul ^a   Montaner, Julio S G ^e   Brun, Scott C ^a   Sun, Eugene ^a  

^a ABBOTT LABORATORIES   (United States)

^b UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^c UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^d UNIVERSITY HEALTH NETWORK   (Canada)

^e UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^f UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^g NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; LAMIVUDINE; LOPINAVIR; NELFINAVIR; RITONAVIR; STAVUDINE; VIRUS RNA;

ARTICLE; CELL COUNT; CONTROLLED STUDY; DRUG RESPONSE; FEMALE; HIGH RISK POPULATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; MAJOR CLINICAL STUDY; MALE; PATIENT; PREDICTION; PRIORITY JOURNAL; RANDOMIZATION; TIME; VIROLOGY;

ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; DOUBLE-BLIND METHOD; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; LAMIVUDINE; MALE; NELFINAVIR; PREDICTIVE VALUE OF TESTS; PYRIMIDINONES; RISK FACTORS; RITONAVIR; RNA, VIRAL; SEX CHARACTERISTICS; STAVUDINE; VIRAL LOAD;

EID: 3242697609     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/422037     Document Type: Article

References (17)

1. Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998; 338:853-60.
2. Paredes R, Mocroft A, Kirk O, et al. Predictors of virological success and ensuing failure in HIV-positive patients starting highly active antiretroviral therapy in Europe. Results from the EuroSIDA Study. Arch Intern Med 2000; 160:1123-32.
3. Grabar S, Pradier C, Le Corfec E, et al. Factors associated with clinical and virological failure in patients receiving a triple therapy including a protease inhibitor. AIDS 2000; 14:141-9.
4. LeMoing V, Chene G, Carrieri MP, et al. Predictors of virological rebound in HIV-1-infected patients initiating a protease inhibitor-containing regimen. AIDS 2002; 16:21-9.
5. Murphy RL, Brun S, Hicks C, et al. ABT-378/ritonavir plus stavudine and lamivudine for the treatment of antiretroviral-naive adults with HIV-1 infection: 48-week results. AIDS 2001; 15:F1-9.
6. Kempf DJ, Isaacson JD, King MS, et al. Analysis of the virologic response with respect to baseline viral phenotype and genotype in protease inhibitor-experienced HIV-1-infected patients receiving lopinavir/ritonavir therapy. Antivir Ther 2002; 7:165-74.
7. King M, Perrin L, Yerly S, Real K, Brun S. Failure to achieve HIV RNA ≤3 copies/mL by week 72 is not associated with loss of virologic response through 4 years of lopinavir/ritonavir-based therapy [abstract PL3.3]. In: Program and abstracts of the Sixth International Congress on Drug Therapy in HIV Infection (Glasgow). Tytherington, UK: The Gardiner-Caldwell Group, 2002:5.
8. Walmsley S, Bernstein B, King M, et al. Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection. N Engl J Med 2002; 346:2039-46.
9. Bancroft TA. Analysis and inference for incompletely specified models involving the use of preliminary tests(s) of significance. Biometrics 1964; 20:427-42.
10. Maggiolo F, Migliorino M, Maserati R, et al. Virological and immunological responses to a once-a-day antiretroviral regimen with didanosine, lamivudine, and efavirenz. Antivir Ther 2001; 6:249-53.
11. Staszewski S, Keiser P, Montaner J, et al. Abacavir-lamivudine-zidovudine vs indinavir-lamivudine-zidovudine in antiretroviral-naive HIV-infected adults: a randomized equivalence trial. JAMA 2001; 285:1155-63.
12. Kempf DJ, King MS, Bernstein B, et al. Incidence of resistance in a double-blind study comparing lopinavir/ritonavir plus stavudine and lamivudine to nelfinavir plus stavudine and lamivudine. J Infect Dis 2004; 189:51-60.
13. Molla A, Vasavanonda S, Kumar G, et al. Human serum attenuates the activity of protease inhibitors toward wild-type and mutant human immunodeficiency virus. Virology 1998; 250:255-62.
14. Zhang KE, Wu E, Patick AK, et al. Circulating metabolites of the human immunodeficiency virus protease inhibitor nelfinavir in humans: structural identification, levels in plasma, and antiviral activities. Antimicrob Agents Chemother 2001; 45:1086-93.
15. Staszewski S, Morales-Ramirez J, Tashima KT, et al. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. N Engl J Med 1999; 341:1865-73.
16. Sanne I, Piliero P, Squires K, Thiry A, Schnittman S. Results of a phase 2 clinical trial at 48 weeks (AI424-207): a dose-ranging, safety, and efficacy comparative trial of atazanavir at three doses in combination with didanosine and stavudine in antiretroviral-naive subjects. J Acquir Immune Defic Syndr 2003; 32:18-29.
17. Schuermann D, Gathe J, Sanne I, Wood R. Efficacy and safety of GW433908/ritonavir once daily in therapy-naive subjects, 48 week results: the SOLO study [abstract PL14.4]. In: Program and abstracts of the Sixth International Congress on Drug Therapy in HIV Infection (Glasgow). Tytherington, UK: The Gardiner-Caldwell Group, 2002:18.